Sara Colombetti Selected Research

cibisatamab

1/2021	Multi-Parameter Quantitative Imaging of Tumor Microenvironments Reveals Perivascular Immune Niches Associated With Anti-Tumor Immunity.
12/2019	Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.
9/2016	In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing.
1/2016	A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
1/2016	Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sara Colombetti Research Topics

Disease

14	Neoplasms (Cancer) 01/2021 - 01/2006
2	Hematologic Neoplasms (Hematological Malignancy) 12/2019 - 10/2018
2	Melanoma (Melanoma, Malignant) 07/2012 - 01/2006
1	Disease Progression 01/2021
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2020
1	Renal Cell Carcinoma (Grawitz Tumor) 11/2020

Drug/Important Bio-Agent (IBA)

5	cibisatamabIBA 01/2021 - 01/2016
4	Carcinoembryonic AntigenIBA 01/2021 - 01/2016
3	Bispecific AntibodiesIBA 01/2021 - 12/2019
3	AntigensIBA 01/2020 - 01/2006
2	AntibodiesIBA 01/2020 - 10/2018
1	Pharmaceutical PreparationsIBA 01/2021
1	CytokinesIBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Lymphocyte Function-Associated Antigen-1 (LFA-1)IBA 01/2021
1	N- propyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (PPTP)IBA 01/2021
1	atezolizumabIBA 11/2020
1	Blocking AntibodiesIBA 11/2020
1	Granzymes (Granzyme)IBA 12/2019
1	Neoplasm Antigens (Tumor Antigens)IBA 12/2019
1	Proteins (Proteins, Gene)FDA Link 12/2019
1	obinutuzumabIBA 10/2018
1	Immunoglobulin G (IgG)IBA 01/2016
1	Biological ProductsIBA 01/2016

Therapy/Procedure

5	Immunotherapy 01/2021 - 01/2006
3	Therapeutics 01/2021 - 07/2012
1	Investigational Therapies (Experimental Therapy) 01/2021
1	Aftercare (After-Treatment) 09/2016